Literature DB >> 35077220

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

Shuai Li1,2,3, Valentina Silvestri4, Goska Leslie2, Timothy R Rebbeck5,6, Susan L Neuhausen7, John L Hopper1, Henriette Roed Nielsen8, Andrew Lee2, Xin Yang2, Lesley McGuffog2, Michael T Parsons9, Irene L Andrulis10,11, Norbert Arnold12,13, Muriel Belotti14,15, Åke Borg16, Bruno Buecher14,15, Saundra S Buys17, Sandrine M Caputo14,15, Wendy K Chung18, Chrystelle Colas14,15, Sarah V Colonna17, Jackie Cook19, Mary B Daly20, Miguel de la Hoya21, Antoine de Pauw14,15, Hélène Delhomelle14,15, Jacqueline Eason22, Christoph Engel23, D Gareth Evans24,25, Ulrike Faust26, Tanja N Fehm27, Florentia Fostira28, George Fountzilas29,30, Megan Frone31, Vanesa Garcia-Barberan21, Pilar Garre21, Marion Gauthier-Villars14,15, Andrea Gehrig32, Gord Glendon10, David E Goldgar33, Lisa Golmard14,15, Mark H Greene31, Eric Hahnen34,35, Ute Hamann36, Helen Hanson37, Tiara Hassan38, Julia Hentschel39, Judit Horvath40, Louise Izatt41, Ramunas Janavicius42,43, Yue Jiao44,45,46, Esther M John47,48, Beth Y Karlan49, Sung-Won Kim50, Irene Konstantopoulou28, Ava Kwong51,52,53, Anthony Laugé14,15, Jong Won Lee54, Fabienne Lesueur44,45,46, Noura Mebirouk44,45,46, Alfons Meindl55,56, Emmanuelle Mouret-Fourme14,15, Hannah Musgrave57, Joanne Ngeow Yuen Yie58,59, Dieter Niederacher27, Sue K Park60,61,62, Inge Sokilde Pedersen63,64,65, Juliane Ramser56, Susan J Ramus66,67, Johanna Rantala68, Muhammad U Rashid36,69, Florian Reichl70, Julia Ritter71, Andreas Rump72, Marta Santamariña73,74,75, Claire Saule14,15, Gunnar Schmidt76, Rita K Schmutzler34,35,77, Leigha Senter78, Saba Shariff79, Christian F Singer70, Melissa C Southey3,80,81, Dominique Stoppa-Lyonnet14,82,83, Christian Sutter84, Yen Tan70, Soo Hwang Teo38,85, Mary Beth Terry86, Mads Thomassen8, Marc Tischkowitz87,88, Amanda E Toland89, Diana Torres36,90, Ana Vega73,74,75, Sebastian A Wagner91, Shan Wang-Gohrke92, Barbara Wappenschmidt34,35, Bernhard H F Weber93,94, Drakoulis Yannoukakos28, Amanda B Spurdle9, Douglas F Easton2, Georgia Chenevix-Trench9, Laura Ottini4, Antonis C Antoniou2.   

Abstract

PURPOSE: To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management.
METHODS: We used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment.
RESULTS: BRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. BRCA2 PVs were associated with risks of male breast (RR = 44.0; 95% CI, 21.3 to 90.9), stomach (RR = 3.69; 95% CI, 2.40 to 5.67), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and prostate (RR = 2.22; 95% CI, 1.63 to 3.03) cancers. The stomach cancer RR was higher for females than males (6.89 v 2.76; P = .04). The absolute risks to age 80 years ranged from 0.4% for male breast cancer to approximately 2.5% for pancreatic cancer for BRCA1 carriers and from approximately 2.5% for pancreatic cancer to 27% for prostate cancer for BRCA2 carriers.
CONCLUSION: In addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks will refine cancer risk management in men and women with BRCA1/2 PVs.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35077220      PMCID: PMC9084432          DOI: 10.1200/JCO.21.02112

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  40 in total

1.  Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.

Authors:  S Paluch-Shimon; F Cardoso; C Sessa; J Balmana; M J Cardoso; F Gilbert; E Senkus
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

2.  A resolution of the ascertainment sampling problem. I. Theory.

Authors:  W J Ewens; N C Shute
Journal:  Theor Popul Biol       Date:  1986-12       Impact factor: 1.570

3.  Risk of breast cancer in male BRCA2 carriers.

Authors:  D G R Evans; I Susnerwala; J Dawson; E Woodward; E R Maher; F Lalloo
Journal:  J Med Genet       Date:  2010-06-28       Impact factor: 6.318

4.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

Authors:  D F Easton; L Steele; P Fields; W Ormiston; D Averill; P A Daly; R McManus; S L Neuhausen; D Ford; R Wooster; L A Cannon-Albright; M R Stratton; D E Goldgar
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

5.  The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Authors:  Roger L Milne; Ana Osorio; Teresa Ramón Y Cajal; Ana Vega; Gemma Llort; Miguel de la Hoya; Orland Díez; M Carmen Alonso; Conxi Lazaro; Ignacio Blanco; Ana Sánchez-de-Abajo; Trinidad Caldés; Ana Blanco; Begoña Graña; Mercedes Durán; Eladio Velasco; Isabel Chirivella; Eva Esteban Cardeñosa; María-Isabel Tejada; Elena Beristain; María-Dolores Miramar; María-Teresa Calvo; Eduardo Martínez; Carmen Guillén; Raquel Salazar; Carlos San Román; Antonis C Antoniou; Miguel Urioste; Javier Benítez
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

6.  Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; D T Bishop; S A Narod; D E Goldgar
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

7.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Mary B Daly; Tuya Pal; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Michael Goggins; Mollie L Hutton; Beth Y Karlan; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Holly J Pederson; Gwen Reiser; Leigha Senter-Jamieson; Kristen Mahoney Shannon; Rebecca Shatsky; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Matthew B Yurgelun; Susan D Darlow; Mary A Dwyer
Journal:  J Natl Compr Canc Netw       Date:  2021-01-06       Impact factor: 11.908

8.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

Review 9.  PARP inhibitors in gastric cancer: beacon of hope.

Authors:  Yali Wang; Kun Zheng; Yongbiao Huang; Hua Xiong; Jinfang Su; Rui Chen; Yanmei Zou
Journal:  J Exp Clin Cancer Res       Date:  2021-06-24

10.  Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Authors:  Tommy Nyberg; Debra Frost; Daniel Barrowdale; D Gareth Evans; Elizabeth Bancroft; Julian Adlard; Munaza Ahmed; Julian Barwell; Angela F Brady; Carole Brewer; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Jacqueline Eason; Helen Gregory; Alex Henderson; Louise Izatt; M John Kennedy; Claire Miller; Patrick J Morrison; Alex Murray; Kai-Ren Ong; Mary Porteous; Caroline Pottinger; Mark T Rogers; Lucy Side; Katie Snape; Lisa Walker; Marc Tischkowitz; Rosalind Eeles; Douglas F Easton; Antonis C Antoniou
Journal:  Eur Urol       Date:  2019-09-06       Impact factor: 20.096

View more
  10 in total

1.  A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes.

Authors:  Esteban Astiazaran-Symonds; Jung Kim; Jeremy S Haley; Sun Young Kim; H Shanker Rao; Regeneron Genetics Center; David J Carey; Douglas R Stewart; Alisa M Goldstein
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

2.  Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.

Authors:  Muriel Rolfes; Julika Borde; Kathrin Möllenhoff; Mohamad Kayali; Corinna Ernst; Andrea Gehrig; Christian Sutter; Juliane Ramser; Dieter Niederacher; Judit Horváth; Norbert Arnold; Alfons Meindl; Bernd Auber; Andreas Rump; Shan Wang-Gohrke; Julia Ritter; Julia Hentschel; Holger Thiele; Janine Altmüller; Peter Nürnberg; Kerstin Rhiem; Christoph Engel; Barbara Wappenschmidt; Rita K Schmutzler; Eric Hahnen; Jan Hauke
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

Review 3.  Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.

Authors:  Raffaella Casolino; Vincenzo Corbo; Philip Beer; Chang-Il Hwang; Salvatore Paiella; Valentina Silvestri; Laura Ottini; Andrew V Biankin
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.

Authors:  Sidrah Shah; Alison Cheung; Mikolaj Kutka; Matin Sheriff; Stergios Boussios
Journal:  Int J Environ Res Public Health       Date:  2022-07-01       Impact factor: 4.614

Review 5.  Male Breast Cancer: From Molecular Genetics to Clinical Management.

Authors:  Matilde Pensabene; Claudia Von Arx; Michelino De Laurentiis
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

6.  Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.

Authors:  Hannes Jürgens; Laura Roht; Liis Leitsalu; Margit Nõukas; Marili Palover; Tiit Nikopensius; Anu Reigo; Mart Kals; Kersti Kallak; Riina Kütner; Kai Budrikas; Saskia Kuusk; Vahur Valvere; Piret Laidre; Kadri Toome; Kadri Rekker; Mikk Tooming; Tiina Kahre; Krista Kruuv-Käo; Katrin Õunap; Peeter Padrik; Andres Metspalu; Tõnu Esko; Krista Fischer; Neeme Tõnisson
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

Review 7.  Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants.

Authors:  Sarah Edaily; Hikmat Abdel-Razeq
Journal:  Onco Targets Ther       Date:  2022-07-27       Impact factor: 4.345

8.  Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations.

Authors:  Louise Wang; Susan M Domchek; Michael L Kochman; Bryson W Katona
Journal:  Genes Cancer       Date:  2022-08-29

Review 9.  Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.

Authors:  Rinat Bernstein-Molho; Eitan Friedman; Ella Evron
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 10.  Endoscopic Surveillance in Patients with the Highest Risk of Gastric Cancer: Challenges and Solutions.

Authors:  Jessica M Long; Jessica Ebrahimzadeh; Peter P Stanich; Bryson W Katona
Journal:  Cancer Manag Res       Date:  2022-10-10       Impact factor: 3.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.